Drugs / Avacincaptad
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05839041 Comparator | May 2023 → Apr 2026 overdue | degeneration of macula and posterior pole | Aviceda Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Avacincaptad | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05839041 ↗ |
| Route | Intravitreal | “Intravitreal injection of 2 mg avacincaptad” NCT05839041 ↗ |